litio orotato

Lithium Orotate

1. Identity and Chemical Characterization

Lithium orotate (C₅H₃LiN₂O₄) is a salt of orotic acid and lithium. Its hydrated form has the molecular formula LiC₅H₃N₂O₄·H₂O. In this compound, lithium is non-covalently bound to an orotate ion, rather than to a carbonate or other ion, and like other salts, dissolves in solution to produce free lithium ions. Lithium orotate consists of lithium, an alkali metal, and orotic acid, a compound produced naturally in the body.

Orotic acid (pyrimidinecarboxylic acid; CAS 65-86-1) is a naturally occurring intermediate in the biosynthesis of pyrimidines. As orotate is a precursor to uracil, orotates may make use of nucleotide transporters (e.g., the uracil transporter) resident in cell membranes.

The pharmacokinetics of lithium orotate in human brains is poorly documented, and there is no known mechanism by which orotate ions could alter the pharmacokinetics of dissociated lithium ions. Experimental measurements of solution conductivity show that lithium salts differ in this measure of ionization. Solutions of organic lithium salts exhibit significantly lower conductivity than inorganic lithium salts, and lithium orotate showed the least conductivity. This result can be interpreted to mean that in solution the lithium–orotate pair and other organic salts behave as a single species.

Common Forms and Preparations

Lithium supplements are sold as pills, liquid capsules, solutions, and syrups of lithium orotate or lithium aspartate. Lithium orotate supplements are typically sold in doses of 5 to 10 milligrams and are often touted as being safer, more natural, or more effective at reaching the brain than other lithium salts like lithium carbonate. The elemental lithium content of lithium orotate is considerably lower by weight than that of the inorganic pharmaceutical salt: each tablet may contain 120 mg of lithium orotate, equating to 3.83 mg of elemental lithium per 100 mg of (organic) lithium orotate, compared to 18.8 mg of elemental lithium per 100 mg of (inorganic) lithium carbonate.

Lithium orotate is marketed as a dietary supplement and has "GRAS" (generally recognized as safe) status. While lithium orotate is capable of providing lithium to the body, like lithium carbonate and other lithium salts, no systematic reviews support the efficacy of lithium orotate and it is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of any medical condition.

2. Natural Sources and Dietary Lithium Context

Lithium orotate as a specific compound is a manufactured supplement and does not occur as such in foods. Lithium orotate does not naturally occur in foods. However, many foods naturally contain elemental lithium, a trace mineral, though typically in very small, variable amounts depending on environmental factors like soil and water composition. Lithium is commonly found in drinking water and in many foods, including grains, vegetables, mustard, kelp, pistachios, dairy, fish, and meat. Dietary intake of elemental lithium was estimated at 0.6 to 3.1 milligrams per day in the United States in 1985.

The lithium content in foods depends heavily on soil composition, water sources, and geographic location where the food was grown.

3. Traditional and Historical Use

Lithium orotate does not have a history of use in classical traditional medicine systems (such as Ayurveda, Traditional Chinese Medicine, or Western herbalism), as it is a specifically synthesized salt. The concept of its use emerged in the 20th century within the context of mineral carrier pharmacology.

Lithium salts have been used for more than half a century to combat the psychiatric manifestations of bipolar disorder. Building on the established efficacy of lithium in treating mania, first demonstrated by Australian psychiatrist John Cade in 1949 through his seminal experiments with lithium salts on guinea pigs and human patients, Nieper promoted lithium orotate in the 1970s as a safer, low-dose alternative to lithium carbonate.

Lithium orotate is most notable for its early use and advocacy by the controversial Hans Nieper in the 1970s, who proposed that orotic acid was a superior carrier compound that could more readily transport inorganic ions across biological membranes. In a two-year open-label study published in 1973, Nieper treated patients with various disorders, including mania, depression, and alcoholism, using low doses of lithium orotate (typically 150–300 mg/day, equivalent to 5–12 mg elemental lithium). He reported mood stabilization, reduced manic symptoms, and improvements in depressive states without the gastrointestinal side effects commonly associated with lithium carbonate, attributing this to orotate's enhanced cellular uptake.

Lithium orotate was studied between 1973 and 1986 as a treatment for medical conditions such as alcoholism and Alzheimer's disease. The reason why lithium orotate is poorly studied as a medication compared to lithium carbonate is concerns raised in 1979 regarding the potential amplified renal toxicity of lithium orotate in comparison to lithium carbonate. These concerns were likely based on the results of the use of excessively high concentrations of lithium orotate in the studies. As a result of these concerns, the clinical application and research of lithium orotate were halted for decades since the 1980s. Still, interest in lithium orotate has been rekindled, and research into its use as medication was resumed in the 2010s.

4. Key Constituents and Mechanisms of Action

Active Component: Lithium Ion (Li⁺)

The pharmacologically active component is the lithium ion. Lithium's main mechanisms of action appear to stem from its ability to inhibit glycogen synthase kinase-3 (GSK-3) activity and also to induce signaling mediated by brain-derived neurotrophic factor. This in turn alters a wide variety of downstream effectors, with the ultimate effect of enhancing pathways to cell survival. In addition, lithium contributes to calcium homeostasis.

GSK-3 Inhibition

The mood stabilizer lithium inhibits glycogen synthase kinase-3 (GSK-3) directly or indirectly by enhancing serine phosphorylation of both α and β isoforms. Lithium robustly protected primary brain neurons from glutamate-induced excitotoxicity; these actions were mimicked by other GSK-3 inhibitors or silencing/inhibiting GSK-3α and/or β isoforms. Lithium rapidly activated Akt to enhance GSK-3 serine phosphorylation and to block glutamate-induced Akt inactivation.

GSK-3 is now known to regulate the actions of more than 25 different transcription factors, thereby exerting a tremendously large effect on regulating the levels of proteins in neurons. For example, GSK-3 inhibits the transcription factor called CREB — which otherwise contributes to cellular resilience and learning and memory, in part by inhibiting the expression of the signaling protein BDNF. Lithium effectively frees CREB to do its beneficial work. Lithium also increases resistance to oxidative stress by reversing GSK-3's inhibition of the transcription factor Nrf2. Moreover, lithium counters GSK-3's activation of the transcription factor p53, which promotes cell death in response to certain stresses.

BDNF and Neurotrophic Signaling

Lithium up-regulated Bcl-2 and suppressed glutamate-induced p53 and Bax. Induction of brain-derived neurotrophic factor (BDNF) was required for lithium's neuroprotection to occur. Lithium can directly and indirectly inhibit constitutively activated GSK-3 by multiple mechanisms, leading to disinhibition of several transcription factors, including cyclic AMP-response element binding protein (CREB), heat-shock factor-1 (HSF-1), and β-catenin, and subsequent induction of major cytoprotective proteins such as brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), heat shock protein (HSP)70, and B-cell lymphoma/leukemia-2 protein (Bcl-2).

Ion Transport and Membrane Effects

The chronic administration of lithium helps to support healthy mood by modulating NMDA receptors in the brain. Lithium also alters sodium transport and interferes with other ion exchange mechanisms, altering nerve conduction. Lithium can replace sodium in extracellular fluid. Lithium's neuroprotective effects were also associated with inhibition of NMDA receptor-mediated calcium influx and downstream signaling.

Proposed Role of the Orotate Carrier

Lithium orotate, most notable for its use and advocacy by Hans Nieper in the 1970s, may represent a treatment option that displays lower dosage requirements relative to lithium carbonate with a subsequent reduction in side effect incidence. Nieper proposed that orotic acid was a mineral carrier that could more readily transport inorganic ions — such as lithium, magnesium, or calcium — across biological membranes.

A proposed but unconfirmed mechanism is that the lithium–orotate complex, because it remains less dissociated in solution than inorganic salts, may cross cell membranes via nucleotide transporters. As orotate is a precursor to uracil, orotates may make use of nucleotide transporters (e.g., the uracil transporter) resident in cell membranes. Non-ionized fluorouracil is a substrate for such transporters, while charged pyrimidines are not, which suggests neutral orotate complexes may also be substrates. Finally, orotate is known to utilize the urate transporter 1 (URAT1) for traversal across membranes in the kidney, which may suggest that passage into the CNS is possible via URAT1 located within the choroid plexus.

It is important to note, however, that Pacholko and Bekar's comprehensive 2021 review notes that no plausible mechanism exists by which orotic acid would significantly alter lithium ion transport across the blood-brain barrier.

5. Scientific Evidence by Area of Use

5.1 Pharmacokinetics: Brain Bioavailability Compared to Lithium Carbonate

Animal/preclinical data — conflicting results; no human pharmacokinetic data.

A study by Kling et al. (1978) found that lithium orotate resulted in brain lithium concentrations three-fold higher than what were observed for equivalent doses of lithium carbonate. While the concentration of lithium within the serum fell over the course of 24 hours in mice treated with either compound, only those injected with lithium orotate displayed a progressive increase in brain lithium levels, which suggests an alternative, and perhaps superior, set of mechanisms underpinning its cellular influx and/or efflux.

A year later, Smith and Schou repeated the experiment at a higher dose (2 mM Li⁺) and found that the higher concentrations in the brain could be possibly accounted for by decreased renal function in rats treated with lithium orotate. The proponents of lithium orotate have since criticized the results by citing the fact that the dose of lithium orotate used in the study was in the toxic range.

A 2022 study by Pacholko and Bekar using lower, non-toxic doses found lithium orotate demonstrated higher brain lithium levels than lithium carbonate while exhibiting improved kidney safety profiles. These contradictory findings suggest dose-dependent pharmacokinetics warrant further investigation. The clinical relevance of potentially enhanced brain lithium concentrations remains unclear.

In a 2023 mouse model of mania published in the Journal of Psychiatric Research, lithium orotate was found to be more potent, efficacious, and long-lasting than lithium carbonate in the blockade of hyperlocomotion. Despite early evidence of reduced dosage requirements relative to lithium carbonate, the use of lithium orotate in psychiatric applications has gone largely unexplored over the past 50 years. These differences likely relate to the observations that lithium orotate did not readily dissociate in solution and utilized alternative transport mechanisms. Furthermore, the researchers observed an absence of adverse effects on markers of kidney and thyroid health with lithium orotate in that mouse study.

5.2 Bipolar Disorder and Mania

Evidence level: Very weak — one uncontrolled human case series only; animal data are promising but preliminary.

Lithium orotate was successfully employed in the treatment of mania in the early 1970s by Hans Nieper, an early proponent for the use of orotic acid as a mineral carrier. His 1973 publication described two years of open-label clinical use at 150–300 mg/day, but the work was published in a generalist pharmacology journal (Agressologie) without randomization, blinding, or a control group. Extrapolation of reported findings is limited by poor methodology of the limited studies.

Bipolar disorder poses a significant public health concern, with roughly one-quarter of sufferers attempting suicide. BD is characterized by manic and depressive mood cycles, the recurrence of which can be effectively curtailed through lithium therapy. Unfortunately, the most frequently employed lithium salt, lithium carbonate, is associated with a host of adverse health outcomes following chronic use: these unwanted effects range from relatively minor inconveniences (e.g., polydipsia and polyuria) to potentially major complications (e.g., hypothyroidism and/or renal impairment). Whether lithium orotate represents a viable alternative for BD in humans remains scientifically unestablished.

5.3 Alcoholism and Substance Use

Evidence level: Weak — single uncontrolled open-label study with significant methodological limitations.

An open study in 42 alcoholic patients evaluated the effect of lithium orotate 150 mg/day taken over 6 months. Lithium orotate intervention demonstrated benefit in treating alcoholism and was also associated with improvements in depression.

The original Sartori (1986) study has been further described as follows: The subjects were 42 alcoholic patients (33 males and 9 females) who were treated with lithium orotate during an alcohol rehabilitation program in a private clinical setting for at least six months. They derived from a total number of 105 patients who received this treatment initially, while the remainder discontinued the treatment within six months. The data were collected from a private practice record and the follow-up varied between six months and 10 years. The 42 patients studied displayed a multitude of complaints in addition to chronic alcoholism. These included liver dysfunction, seizure disorders, headaches, hyperthyroidism, affective disorders, Meniere's syndrome, liver and lung cancers.

The 1986 study by Sartori demonstrated reduced alcohol cravings, with 23 patients showing no relapse over 1–10 years and concurrent alleviation of associated depressive symptoms. However, significant methodological limitations undermine these findings, including the absence of a control group, non-blinded assessment, and minimal outcome standardization. No additional studies concerning the use of lithium orotate in the treatment of alcoholism have been conducted outside of the work by Sartori (1986).

5.4 Alzheimer's Disease and Neurodegeneration

Evidence level: Preclinical (animal) data showing notable effect; one registered clinical trial not yet recruiting; no completed human trials with lithium orotate specifically.

Researchers tested whether replacing lithium might influence Alzheimer's disease pathology. Lithium carbonate is used as a mood stabilizer to treat bipolar disorder, but the researchers found that it is highly attracted to negatively charged amyloid plaques. The team tested 16 different lithium salts to find an alternative and settled on the organic salt lithium orotate. The researchers tested lithium carbonate and lithium orotate in AD mouse models at low doses in drinking water. Treatment with lithium carbonate had little effect. But lithium orotate significantly reduced amyloid plaque burden and tau tangle accumulation. Lithium orotate also restored synapses and reversed memory loss in AD mice, yet lithium carbonate did not.

The team further evaluated whether dietary lithium could have a protective effect in normal brain aging. They found that low-dose lithium orotate prevented synapse loss and reversed cognitive decline in aging mice. Long-term treatment with lithium orotate did not show toxicity. This work was published in Nature in 2025 (Aron et al.).

A clinical trial titled "LiO-AD: Lithium Orotate in Alzheimer's Disease Feasibility, Biomarker Engagement, and Clinical Response" has been registered at Johns Hopkins University (NCT07459959), with an estimated start date of October 2026 and a primary completion date of June 2029. As of the current date, this trial has not yet recruited participants.

5.5 Low-Dose Lithium, Mood, and Suicide Prevention

Evidence level: Ecological associations and meta-analyses (for lithium in water); preliminary for orotate-specific use in mood.

Findings from a systematic review and meta-analysis of ecological studies suggest that naturally occurring lithium in drinking water may have the potential to reduce the risk of suicide and may possibly help in mood stabilisation, particularly in populations with relatively high suicide rates and geographical areas with a greater range of lithium concentration in the drinking water. However, causality cannot be established from ecological studies.

Importantly, a large individual-level cohort study nuanced these findings: individual-level register-based data on the entire Danish adult population (3.7 million individuals) from 1991 to 2012 were linked with a five-year time-weighted average lithium exposure level from drinking water. This was the first such study at an individual level with long follow-up. The mean lithium level in drinking water was 11.6 μg/L ranging from 0.6 to 30.7 μg/L. No significant association was found between increasing lithium exposure and decreasing suicide rate. The findings demonstrate that there does not seem to be a protective effect of exposure to lithium on the incidence of suicide with levels below 31 μg/L in drinking water.

A separate meta-analysis of lithium in drinking water and suicide found a statistically significant inverse association: lithium in drinking water was negatively associated with suicide mortality in the general population (OR = 0.42; 95% CI: 0.27 to 0.67; p-value <0.01). Evidence thus remains mixed and is not specific to lithium orotate.

A 2025 cross-sectional survey examined community use of over-the-counter lithium supplements: a cross-sectional, opportunistic survey of 211 participants aged ≥18 years who disclosed taking over-the-counter lithium supplements was conducted. The survey assessed sample demographics, supplement details, overall perspectives, and personal experiences. The most common form of lithium supplement taken was aspartate at 10 mg once per day, although lithium orotate and ionic lithium were also frequently used. This may be partly attributable to the notable methodological concerns of the only two clinical studies published of lithium orotate.

5.6 Aging and Longevity

Evidence level: Preclinical (invertebrate models) only; no human data.

Limited studies have reported increased longevity in Caenorhabditis elegans worms with low-dose lithium (i.e., 45% increase in median lifespan and a 16% increase in maximal lifespan). Suggestions of enhanced stem-cell production and longevity appear in the literature, but clinical studies are lacking.

6. Body Systems Associated with Lithium Orotate

• Central nervous system: Substantial in vitro and in vivo evidence of neurotrophic and neuroprotective effects of lithium suggests that it may also have considerable potential for the treatment of neurodegenerative conditions.
• Psychiatric/mood systems: Bipolar disorder is characterized by manic and depressive mood cycles, the recurrence of which can be effectively curtailed through lithium therapy. Whether lithium orotate specifically addresses these conditions in humans is unestablished.
• Renal system: Three categories of lithium nephrotoxicity can be distinguished: acute lithium intoxication, nephrogenic diabetes insipidus (NDI), and chronic kidney disease (CKD). These concerns have historically applied to lithium salts broadly.
• Thyroid: Among the most frequent long-term effects of lithium are hypothyroidism and hyperparathyroidism.
• Neurogenesis: In primary rat hippocampal progenitor cultures, long-term lithium treatment promotes the conversion of these progenitor cells into neurons through the GSK-3β inhibition/β-catenin activation pathway.

7. Dosages Reported in Studies

Only dosages explicitly stated in the primary literature are listed here.

• Nieper (1973), open-label clinical study: Typically 150–300 mg/day of lithium orotate, equivalent to 5–12 mg elemental lithium.
• Sartori (1986), alcoholism open-label study: 150 mg/day lithium orotate (about 5.7 mg elemental lithium).
• Acute overdose case (Pauzé and Brooks, 2007): An 18-year-old woman ingested 18 tablets; each tablet contained 120 mg of lithium orotate (3.83 mg of elemental lithium per 100 mg of lithium orotate).
• Typical over-the-counter supplement dose: Supplemental lithium orotate typically comes in 120 or 130 mg capsules or tablets containing 5 mg of elemental lithium.
• NOAEL from preclinical toxicology: No toxicity or target organs were identified in a preclinical study; therefore, a no-observed-adverse-effect level (NOAEL) was determined as 400 mg/kg body weight/day, the highest dose tested.

8. Safety Considerations and Drug Interactions

Regulatory and Toxicological Status

The 2021 ScienceDirect-published study was the first preclinical toxicologic evaluation of lithium orotate. No in vitro or in vivo genotoxic effects were observed in a standard test battery. No treatment-related adverse effects were observed in Wistar rats. No target organs were identified in Wistar rats. Lithium orotate, the salt of lithium and orotic acid, has been marketed for decades as a supplemental source of lithium with few recorded adverse events.

Renal Toxicity Concern

Although evidence for enhanced brain availability was initially found, research into lithium orotate was discontinued largely due to studies that demonstrated lithium orotate to increase impairment of kidney function when used at concentrations equivalent to lithium carbonate. Contrasting studies performed in 1978 and 1979 yielded two important findings: (1) lithium orotate yielded significantly greater concentrations of the lithium ion in the brain than was observed for equivalent doses of lithium carbonate, and (2) lithium orotate impaired renal function to a greater extent than lithium carbonate when employed at concentrations of 2 mmol Li⁺/kg body weight. The 2022 mouse study by Pacholko and Bekar, however, found a more favorable renal profile at lower doses: unlike the 1979 study, these mice had lower rates of renal problems with orotate than carbonate, as well as less polydipsia and fewer thyroid problems.

If the increased ease of membrane transport associated with lithium orotate compared to lithium carbonate is not unique to the blood-brain barrier and/or elements of the CNS, then the elevated accumulation of lithium within off-target organs could accelerate development/risk of complications, for example, renal dysfunction. With that being said, there have been no reported cases of death or serious side-effects in over 40 years of use in North America.

Clinical Case Reports of Toxicity

A case of mild, acute lithium toxicity was reported after the intentional misuse of a lithium-containing dietary supplement obtained over the Internet. An 18-year-old woman presented to the emergency department after ingesting 18 tablets of a supplement containing lithium orotate. The patient complained of nausea and reported one episode of emesis. Her examination revealed normal vital signs. The only finding was a mild tremor without rigidity. Almost 90 minutes after the ingestion, her serum lithium level was 0.31 mEq/L, a urine drug screen was negative, and an electrocardiogram showed a normal sinus rhythm.

A separate published case report from a Dutch hospital illustrates a clinically important masking risk: a 38-year-old woman with pelvic inflammatory disease had been diagnosed with a tubo-ovarian abscess, for which antibiotic therapy with metronidazole and levofloxacin was indicated. Because the patient was already taking lithium she was prescribed clindamycin instead of metronidazole, a drug that interacts with lithium, and naproxen could not be prescribed to reduce pain. However, the lithium taken by the patient turned out to be a dietary supplement containing lithium orotate obtained via the Internet. Because the serum lithium level proved to be below 0.05 mmol/L, clindamycin was still replaced by metronidazole, and naproxen could be started. This case highlights that supplement use can mislead clinicians into adjusting prescriptions unnecessarily.

Drug Interactions

Lithium, regardless of salt form, is eliminated almost entirely by the kidneys. Lithium is not metabolised and is almost entirely eliminated by the kidneys. As a result, serum lithium levels are sensitive to physiological factors that affect renal function, including age, dehydration, sodium balance, and haemodynamics. The following drug classes are documented to interact with lithium ions:

• NSAIDs: The majority of NSAIDs promote an increase in lithium levels, and some, like ibuprofen and naproxen, show great interindividual variability. Naproxen can increase serum lithium levels by up to 41.9% in some individuals.
• Diuretics: Thiazide diuretics have demonstrated the greatest potential to increase lithium concentrations, with a 25 to 40% increase in concentrations often evident after initiation of therapy.
• ACE inhibitors and angiotensin receptor blockers: ACE inhibitors, NSAIDs, and certain antidepressants pose risks when taken alongside lithium, as they can either increase toxicity or lead to serious side effects. ACE inhibitors and angiotensin II receptor antagonists increase the chance of lithium toxicity.
• Sodium and hydration status: Several risk factors for intoxication are already identified like old age, drugs (diuretics, NSAIDs), renal insufficiency, renal artery stenosis, hyponatremic and hypovolemic conditions (cirrhosis, cardiac congestive heart failure).

While toxicity risk appears lower than with prescription lithium due to reduced elemental lithium content, all lithium compounds can potentially cause adverse effects affecting kidney function, thyroid activity, cardiovascular function, and neurological status.

Thyroid Effects

Among the most frequent long-term effects documented for lithium are hypothyroidism and hyperparathyroidism. The 2022 Pacholko and Bekar mouse study found that lithium orotate showed a safer kidney profile than lithium carbonate, and both had an increased TSH only in females, but the increase was lower in the orotate group.

Evidence Limitations and Research Gaps

While accessible as a supplement, empirical human evidence on neuropsychiatric effects is lacking. A review by the Alzheimer's Drug Discovery Foundation found no credible evidence to support claims that lithium orotate supplements are safer, more natural, or more effective at reaching the brain than other lithium salts like lithium carbonate. Extrapolation of reported findings is limited by poor methodology of the limited studies.

There is one certainty regarding the future of lithium orotate in psychiatric applications: more research is needed. A recent systematic review collating studies of sub-therapeutic lithium reported promising evidence for safety, as well as benefits to cognition and mood, but this review addressed low-dose lithium broadly, not lithium orotate specifically. The Johns Hopkins clinical trial registered in 2026 (NCT07459959) will represent the first rigorous human evaluation of lithium orotate in Alzheimer's disease, with results anticipated no earlier than 2029.

References

• NCATS Inxight Drugs — Lithium Orotate Substance Record
• Wikipedia — Lithium Orotate (with cited primary literature)
• Pacholko AG, Bekar LK. "Lithium orotate: A superior option for lithium therapy?" Brain and Behavior. 2021. PMC8413749
• Pacholko AG, Bekar LK. "Different pharmacokinetics of lithium orotate inform why it is more potent, effective, and less toxic than lithium carbonate in a mouse model of mania." J Psychiatr Res. 2023.
• Pacholko AG, Bekar LK. bioRxiv preprint: "Different pharmacokinetics of lithium orotate…" 2022.
• Pauzé DK, Brooks DE. "Lithium toxicity from an Internet dietary supplement." J Med Toxicol. 2007. PMC3550087
• Survey: "A Survey Exploring People's Experiences With Lithium Bought as a Supplement." PMC11954165
• Stice CP et al. "A toxicological evaluation of lithium orotate." Regulatory Toxicology and Pharmacology. 2021.
• Sartori HE. "Lithium orotate in the treatment of alcoholism and related conditions." Alcohol. 1986;3(2):97–100. PubMed 3718672
• Shahid Bashir Z et al. "Novel Insights into Lithium's Mechanism of Action: Neurotrophic and Neuroprotective Effects." PMC2889681
• Chuang DM et al. "GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity." PMC3152742
• Lyman M et al. "Neuroprotective action of lithium in disorders of the central nervous system." PMC3172812
• "Lithium to the Rescue." PMC4938258
• NIH Research Matters: "Lithium levels tied to Alzheimer's disease and dementia." 2025.
• ClinicalTrials.gov: NCT07459959 — LiO-AD: Lithium Orotate in Alzheimer's Disease (Johns Hopkins University)
• Knudsen NN et al. "Lithium in Drinking Water and Incidence of Suicide: A Nationwide Individual-Level Cohort Study." PMC5486313
• Memon A et al. "Association between naturally occurring lithium in drinking water and suicide rates: systematic review and meta-analysis." British Journal of Psychiatry. 2020.
• Rahnama Nia M et al. "Relationship between suicide mortality and lithium in drinking water: A systematic review and meta-analysis." Journal of Affective Disorders. 2020.
• Smith DF. "Lithium orotate, carbonate and chloride: pharmacokinetics, polydipsia and polyuria in rats." British Journal of Pharmacology. 1976.
• Finley PR et al. "Clinical relevance of drug interactions with lithium." Clin Pharmacokinet. 1995. PubMed 8521679
• Nunes PV et al. "Lithium interactions with non-steroidal anti-inflammatory drugs and diuretics — A review." Rev Psiq Clín. 2009.
• Shine B et al. "Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification." PMC6215627
• Lithium nephrotoxicity: systematic review and meta-analysis. PMC12921164
• Alzheimer's Drug Discovery Foundation Cognitive Vitality: "Lithium — Dietary."
• Dietary Lithium, Silicon, and Boron: An Updated Critical Review. Nutrients. 2025. PMC12899721
• Confusion caused by dietary supplement lithium orotate. PubMed 28421576
• An Overview of the Effects of Lithium on Alzheimer's Disease: A Historical Perspective. PMC12030194